All patients (N = 151) | NELNs | |||
---|---|---|---|---|
≤15 (N = 98) | > 15 (N = 53) | |||
Variables | P value | |||
Sex, n (%) | 0.853* | |||
Male | 87 (57.6%) | 57 (58.2%) | 30 (56.6%) | |
Female | 64 (42.4%) | 41 (41.8%) | 23 (43.4%) | |
Race, n (%) | 0.001*** | |||
White patients | 104 (68.9%) | 69 (70.4%) | 35 (66.0%) | |
Black patients | 26 (17.2%) | 22 (22.4%) | 4 (7.6%) | |
Other patients | 21 (13.9%) | 7 (7.2%) | 14 (26.4%) | |
Age (year), n (%) | 0.155* | |||
≤ 60 | 42 (27.8%) | 31 (31.6%) | 11 (20.8%) | |
> 60 | 109 (72.2%) | 67 (68.4%) | 42 (79.2%) | |
Tumor differentiation, n (%) | 0.325* | |||
Well | 20 (13.2%) | 10 (10.2%) | 10 (18.9%) | |
Moderate | 82 (54.3%) | 55 (56.1%) | 27 (50.9%) | |
Poor | 49 (32.5%) | 33 (33.7%) | 16 (30.2%) | |
pT stage, n (%) | 0.126* | |||
T1 | 61 (40.4%) | 40 (40.8%) | 21 (39.6%) | |
T2 | 30 (19.9%) | 15 (15.3%) | 15 (28.3%) | |
T3 | 60 (39.7%) | 43 (43.9%) | 17 (32.1%) | |
Tumor location, n (%) | 0.129*** | |||
Upper | 15 (9.9%) | 13 (13.3%) | 2 (3.8%) | |
Middle | 75 (49.7%) | 49 (50.0%) | 26 (49.1%) | |
Lower | 61 (40.4%) | 36 (36.7%) | 25 (47.1%) | |
Tumor length (cm) | ||||
Median (interquartile range) | 3.0 (2.6) | 3.5 (2.5) | 2.5 (2.5) | 0.121** |